Shares Magazine
55.25p-2.25 (-3.91 %)19 Jan 2021, 14:37
Jump to:
Redx Pharma PLC Fundamentals
| Company Name | Redx Pharma PLC | Last Updated | 2021-01-19 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 273.887 m | Market Cap | £151.32 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.03 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.4631 | Debt Equity Ratio | 1.5648 |
| Asset Equity Ratio | 3.8488 | Cash Equity Ratio | 0.8555 |
| Quick Ratio | 1.1484 | Current Ratio | 1.45 |
| Price To Book Value | 0 | ROCE | 0 |
Redx Pharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Redx Pharma PLC Company Financials
| Assets | 2019 | 2018 |
|---|---|---|
| Tangible Assets | £134,000.00 | £191,000.00 |
| Intangible Assets | £417,000.00 | £423,000.00 |
| Investments | 0 | 0 |
| Total Fixed Assets | £551,000.00 | £614,000.00 |
| Stocks | 0 | 0 |
| Debtors | £445,000.00 | £818,000.00 |
| Cash & Equivalents | £3.70 m | £6.47 m |
| Other Assets | 0 | 0 |
| Total Assets | £6.36 m | £10.32 m |
| Liabilities | 2019 | 2018 |
|---|---|---|
| Creditors within 1 year | £4.87 m | £3.95 m |
| Creditors after 1 year | 0 | £605,000.00 |
| Other Liabilities | 0 | 0 |
| Total Liabilities | £4.87 m | £4.55 m |
| Net assets | £1.49 m | £5.76 m |
| Equity | 2019 | 2018 |
|---|---|---|
| Called up share capital | £1.26 m | £1.26 m |
| Share Premium | £33.26 m | £33.26 m |
| Profit / Loss | -£6.33 m | -£10.15 m |
| Other Equity | £1.49 m | £5.76 m |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | £1.49 m | £5.76 m |
| Ratios | 2019 | 2018 |
|---|---|---|
| Debt Ratio | 0 | 0 |
| Debt-to-Equity | 0 | 0 |
| Assets / Equity | 3.8488 | 3.8488 |
| Cash / Equity | 0.8555 | 0.8555 |
| EPS | -£0.04 | -£0.06 |
| Cash Flow | 2019 | 2018 |
|---|---|---|
| Cash from operating activities | -£4.67 m | -£17.18 m |
| Cashflow before financing | -£2.80 m | -£17.23 m |
| Increase in Cash | -£2.77 m | -£17.34 m |
| Income | 2019 | 2018 |
|---|---|---|
| Turnover | £3.13 m | £129,000.00 |
| Cost of sales | £350,000.00 | 0 |
| Gross Profit | £2.78 m | £129,000.00 |
| Operating Profit | -£6.25 m | -£10.17 m |
| Pre-Tax profit | -£6.33 m | -£10.15 m |
Redx Pharma PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Redx Pharma PLC is a UK biotechnology company whose vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. |
| Latest Interim Date | 30 Jun 2020 |
| Latest Fiscal Year End Date | 27 Jan 2021 |
Redx Pharma PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2020-12-21 | Mr. Iain Gladstone Ross | Non-Executive Director,Chairman |
| 2018-02-19 | Dr. Frank Murdoch Armstrong | Non-Executive Director,Chairman |
| 2020-12-21 | Mr. Peter Eric Presland | Non-Executive Director |
| 2018-02-19 | Mr. Norman Molyneux | Non-Executive Director |
| 2018-02-19 | Dr. Neil David Murray | Executive Director,Chief Executive Officer |
| 2018-02-19 | Dr. Peter Jackson | Non-Executive Director |
| 2017-03-30 | Dr. Derek Lindsay | Executive Director,Chief Operating Officer |
| 2017-03-30 | Mr. Philip John Tottey | Executive Director,Chief Financial Officer |
| 2017-04-20 | Mr. Peter McPartland | Non-Executive Director |
| 2020-01-09 | Dr. Bernhard Jurgen Kirschbaum | Non-Executive Director |
| 2020-03-17 | Mr. Dominic Nicholas Jackson | Executive Director,Chief Financial Officer |
| 2020-12-23 | Ms. Lisa Mary Whewell Anson | Executive Director,Chief Executive Officer |
| 2020-06-30 | Dr. James Robert Mead | Executive Director,Chief Financial Officer |
| 2020-12-21 | Ms. Sarah Gordon Wild | Non-Executive Director |
Redx Pharma PLC Contact Details
| Company Name | Redx Pharma PLC |
|---|---|
| Address | Block 33, Mereside, Alderley Park, Macclesfield, SK10 4TG |
| Telephone | +44 1625469900 |
| Website | http://www.redxpharma.com |
Redx Pharma PLC Advisors
| Auditor | RSM |
|---|---|
| Phone | +44 1618304000 |
| Fax | +44 1618304001 |
| Stockbroker | WG Partners |
|---|
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
| Nominated Adviser | Cantor Fitzgerald Europe |
|---|---|
| Phone | +44 2078947895 |
| Stockbroker | Cantor Fitzgerald Europe |
|---|---|
| Phone | +44 2078947895 |
| Solicitor | DWF LLP |
|---|---|
| Phone | +44 1612283702 |
| Fax | +44 1618352407 |
| Registrar | Equiniti Ltd. |
|---|---|
| Phone | +44 1214157082 |
Sign up to our
daily email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Indivior PLC | 130.30 | 9.31 |
| Wetherspoon ( J.D.) PLC | 1,186.00 | 4.40 |
| Wizz Air Holdings PLC | 4,490.00 | 4.27 |
| Easyjet PLC | 847.40 | 3.85 |
| Smith & Nephew PLC | 1,626.00 | 3.60 |
| Mitchells & Butlers PLC | 256.50 | 3.22 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Entain PLC | 1,205.00 | -14.75 |
| Wood Group (John) PLC | 329.90 | -5.47 |
| Ao World PLC | 359.86 | -4.67 |
| Premier Foods PLC | 103.60 | -4.07 |
| Standard Chartered PLC | 473.80 | -3.48 |
| Babcock International Group PLC | 198.70 | -3.21 |
